AbbVie, BioArctic in Pact for Parkinson’s Disease
AbbVie has formed a collaboration with BioArctic, a Stockholm, Sweden-based biopharmaceutical company, to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein for treating Parkinson’s disease and other potential indications. Financal terms of the agreement were not disclosed.
Mutations in alpha-synuclein are linked to development of Parkinson’s disease, according to information from BioArctic. Soluble aggregates of the alpha-synuclein protein are considered to be toxic to neurons and lead to the deposits that are a hallmark of the disease, according to the company.